With a solid balance sheet and growing footprint in the pharmaceutical manufacturing supply chain, Kneat expects to outpace 2025’s incremental ARR. While Kneat anticipates typical second-half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results